Eleonora Leggiero, CMC Project Lead at Valo Therapeutics Italy, holds a PhD in Genetics and Molecular Medicine and a specialization in Hospital Pharmacy from the University of Naples Federico II, Italy. She has over 15 years of experience in advanced therapies, with a focus on viral vector development, gene therapy, and CMC activities supporting the development and manufacturing of viral vector–based technologies.
Before joining Valo Therapeutics Italy, she worked at InnovAAVector (Pozzuoli, Italy) as Process Development and Technology Transfer Manager, where she led projects related to viral vector process development and technology transfer, coordinating upstream and downstream process optimization, analytical method implementation, and collaborations with industrial partners.
Earlier in her career, Dr. Leggiero worked at CEINGE – Advanced Biotechnologies in Naples, where she contributed to several research programs focused on gene therapy and viral vector platform development. Her work included the development of adenoviral, lentiviral, and retroviral vector systems, the coordination of multidisciplinary collaborations, and regulatory activities related to the use of genetically engineered microorganisms.
At Valo Therapeutics Italy, she leads CMC activities supporting the process development and upscaling of the PeptiCRAd viral vector platform. Drawing on her experience in viral vector bioprocess development and technology transfer, she also contributes to broader scientific coordination, interactions with external partners, and the operational advancement of the program.
